Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure

DOI Web Site 参考文献20件
  • Fujisue Koichiro
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Ito Miwa
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Miyazaki Medical Association Hospital
  • Matsuzawa Yasushi
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Arima Yuichiro
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Takashio Seiji
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Sueta Daisuke
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Araki Satoshi
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Hanatani Shinsuke
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Yamanaga Kenshi
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Yamamoto Masahiro
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Kaneko Shozo
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Yamamoto Eiichiro
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Matsushita Kenichi
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Department of Cardiology, Saitama Medical University International Medical Center
  • Soejima Hirofumi
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
  • Tsujita Kenichi
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

抄録

<p>Background: Neither the efficacy nor safety of elobixibat has been investigated in the treatment of chronic constipation in patients with heart failure (HF).</p><p>Methods and Results: In this prospective, single-center, single-arm study elobixibat (10 mg/day) was administered for 12 weeks to 18 HF patients with chronic constipation defined according to the Rome IV criteria. Spontaneous bowel movement (SBM), stool consistency as measured by the Bristol Stool Form Scale, and degree of straining during defecation were recorded. In addition, biomarkers, blood pressure (BP) measured by ambulatory monitoring, and adverse events were assessed. Although there was no significant difference, the frequency of SBM increased by 2.0/week from baseline to Week 12. Both the degree of straining during defecation and low-density lipoprotein cholesterol (LDL-C) levels were significantly decreased at Week 12 (straining, −0.79 [95% confidence interval (CI), −1.40 to −0.17]; LDL-C, −10.4 mg/dL [95% CI, −17.9 to −2.9]). Although not significant, the difference in BP before and after defecation tended to decrease from baseline by approximately 10 mmHg at Week 12. Serious adverse events were not observed.</p><p>Conclusions: Elobixibat reduced the degree of straining during defecation, and improved the lipid profile in HF patients with chronic constipation.</p>

収録刊行物

  • Circulation Reports

    Circulation Reports 6 (3), 55-63, 2024-03-08

    一般社団法人 日本循環器学会

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ